Bridgeway Capital Management’s TriSalus Life Sciences TLSI Stock Holding History

Bridgeway Capital Management’s Portfolio TLSI Stock Details TLSI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$316K	Hold	69,500	–	–	0.01%	969
2026 Q1	$278K	Hold	69,500	–	–	0.01%	953
2025 Q4	$485K	Hold	69,500	–	–	0.01%	823
2025 Q3	$323K	Sell	69,500 -5,900	-8%	-$27.6K	0.01%	905
2025 Q2	$411K	Buy	75,400 +10,400	+16%	+$55.8K	0.01%	806
2025 Q1	$359K	Hold	65,000	–	–	0.01%	806
2024 Q4	$326K	Buy	65,000 +50,000	+333%	+$211K	0.01%	905
2024 Q3	$69.2K	Buy	+15,000	New	+$79.4K	﹤0.01%	1192

Other funds holding TLSI

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Cerity Partners New York $82.7B AUM 28.53% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

WPC

White Pine Capital Bloomington, Minnesota $423M AUM 67.01% 1-Year Est. Return

TSW

Thompson Siegel & Walmsley Richmond, Virginia $5.57B AUM 9.46% 1-Year Est. Return

Bridgeway Capital Management's TLSI Position: Q2 2026 in Review

Bridgeway Capital Management held its TriSalus Life Sciences (TLSI) position steady in Q2 2026 at 69,500 shares worth $316K. The position accounts for 0.01% of the portfolio, ranked #969.

Bridgeway Capital Management first reported a position in TLSI in Q3 2024 and has held it in 8 quarters since. The position peaked at $485K in Q4 2025. 79 funds tracked by Wall St. Rank hold TLSI as of Q2 2026.

Bridgeway Capital Management held 69,500 shares of TriSalus Life Sciences worth $316K as of Q2 2026.
Bridgeway Capital Management left its TriSalus Life Sciences share count unchanged in Q2 2026.
TriSalus Life Sciences made up 0.01% of Bridgeway Capital Management's portfolio in Q2 2026, its #969 holding.
Bridgeway Capital Management first reported a position in TriSalus Life Sciences in Q3 2024 and has held it in 8 quarters since.
Bridgeway Capital Management's TriSalus Life Sciences position peaked at $485K in Q4 2025.
79 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q2 2026.

Based on Bridgeway Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.